Article · Health news

MHRA authorises orforglipron (Foundayo)

Health news Published · sources checked

The MHRA authorised orforglipron (Foundayo), a GLP-1 tablet, for weight management and type 2 diabetes, saying the UK is the first country in Europe to do so.

Key points

  • The MHRA authorised orforglipron (Foundayo) on 10 August 2026.
  • The MHRA says the UK is the first country in Europe to authorise this GLP-1 tablet for weight management and type 2 diabetes.
  • For weight management it is licensed for adults.
  • For type 2 diabetes it is licensed to improve blood sugar control in people whose diabetes is not controlled well enough.

What was announced

The MHRA says it authorised orforglipron, sold as Foundayo, on 10 August 2026. It describes orforglipron as a GLP-1 tablet, and says the UK is the first country in Europe to authorise it for weight management and type 2 diabetes.

What the authorisation covers

For weight management, the licence covers adults. For type 2 diabetes, it is licensed to improve glycaemic (blood sugar) control in people whose diabetes is insufficiently controlled.

More guides and news

Educational content. This article summarises public guidance and announcements in plain English for education. It is not medical advice and it cannot say what is right for you: speak to a clinician about your own health, call NHS 111 if you are unsure what to do and 999 in an emergency.